Table 1.
Demographics and baseline characteristics of patients with dMMR, MSI-H or hypermutated endometrial or ovarian cancer
| Characteristic | |
|---|---|
| Age (median, range) | 64 (36–87) |
| Ethnicity (n, %) | |
| Non-Hispanic | 31 (89%) |
| Hispanic | 3 (9%) |
| Ethnicity not known | 1 (3%) |
| Race (n, %) | |
| White | 27 (77%) |
| Black | 4 (11%) |
| Asian | 2 (6%) |
| Other/Unknown | 2 (6%) |
| Stage at diagnosis (n, %) | |
| I | 10 (29%) |
| II | 6 (17%) |
| III | 12 (34%) |
| IV | 7 (20%) |
| Histology (n, %) | |
| Endometrioid FIGO G1 | 8 (23%) |
| Endometrioid FIGO G2 | 8 (23%) |
| Endometrioid FIGO G3 | 13 (37%) |
| Clear cell carcinoma | 2 (6%) |
| Dedifferentiated/Undifferentiated | 4 (11%) |
| Molecular subtype (n, %) | |
| Germline MMR mutation | 5 (14%) |
| MLH1 promoter hypermethylation | 23 (66%) |
| Other/Unknowna | 7 (20%) |
| No. of prior lines of cytotoxic therapy (n, %) | |
| 1 | 30 (86%) |
| 2 | 4 (11%) |
| 3 | 1 (3%) |
a Other molecular subtypes; see Supplementary Table 1 for more information.
FIGO, International Federation of Gynecology and Obstetrics.